Company news

Madrigal Pharmaceuticals, Inc. news in 2024

Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

November 5, 2024

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

October 30, 2024

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

October 29, 2024

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

October 20, 2024

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

October 17, 2024

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

October 1, 2024

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

September 30, 2024

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

September 29, 2024

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 25, 2024

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

August 6, 2024

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

August 1, 2024

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

July 23, 2024

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

June 5, 2024

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

May 28, 2024

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 6, 2024

Madrigal Statement on the Passing of Dr. Stephen Harrison

April 23, 2024

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

April 22, 2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 15, 2024

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

April 8, 2024

Madrigal Pharmaceuticals Announces Proposed Public Offering

March 17, 2024

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

March 17, 2024

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

March 13, 2024

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

March 4, 2024

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

February 27, 2024

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

February 7, 2024

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

January 28, 2024

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

January 3, 2024

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024